ID   LA-N-6
AC   CVCL_1363
SY   LAN-6; LAN6; LA-N-6(OAN)
DR   CLO; CLO_0037081
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473429
DR   cancercelllines; CVCL_1363
DR   Cell_Model_Passport; SIDM00330
DR   ChEMBL-Cells; CHEMBL3308206
DR   ChEMBL-Targets; CHEMBL2366123
DR   Cosmic; 697283
DR   Cosmic; 717430
DR   Cosmic; 848929
DR   Cosmic; 930067
DR   Cosmic; 949170
DR   Cosmic; 1019942
DR   Cosmic; 1109105
DR   Cosmic; 1109366
DR   Cosmic; 1161993
DR   Cosmic; 1167408
DR   Cosmic; 1526630
DR   Cosmic; 1890102
DR   Cosmic; 2301577
DR   Cosmic; 2393637
DR   Cosmic-CLP; 949170
DR   DepMap; ACH-001355
DR   DSMZ; ACC-674
DR   DSMZCellDive; ACC-674
DR   EGA; EGAS00001000978
DR   GDSC; 949170
DR   GEO; GSM1670032
DR   GEO; GSM2371240
DR   GEO; GSM2394373
DR   IARC_TP53; 23822
DR   IARC_TP53; 27562
DR   LINCS_LDP; LCL-1988
DR   PharmacoDB; LAN6_819_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1363
DR   Wikidata; Q54901879
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=8242562;
RX   PubMed=11507071;
RX   PubMed=15150091;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=20164919;
RX   PubMed=23202128;
RX   PubMed=24792489;
RX   PubMed=25884760;
RX   PubMed=27397505;
RX   PubMed=28350380;
RX   PubMed=28636942;
RX   PubMed=30894373;
RX   PubMed=31631027;
RX   PubMed=35839778;
WW   http://www.cccells.org/dl/NB_Data_Sheets/LA-N-6_Cell_Line_Data_Sheet_COGcell_org.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Characteristics: Neuroblastic type (N-type) (PubMed=15720811).
CC   Characteristics: Has long and heterogeneous telomeres and no telomerase activity. Its telomeres shortens continuously at an average rate of 55 base pairs per population doubling (PubMed=28636942).
CC   Doubling time: 3 days (PubMed=28636942); ~1 week (DSMZ=ACC-674).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=28636942).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Asp1091Asn (c.3271G>A); ClinVar=VCV000218628; Zygosity=Heterozygous (PubMed=18724359; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep tyrosine phosphoproteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.47%; Native American=23.6%; East Asian, North=3.12%; East Asian, South=0%; South Asian=0%; European, North=42.61%; European, South=28.2% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): COG; Cosmic-CLP; DepMap; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 10,12
ST   D18S51: 16
ST   D19S433: 14
ST   D21S11: 30,32.2
ST   D2S1338: 18,19
ST   D3S1358: 15
ST   D5S818: 10,12
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 18,21
ST   Penta D: 13
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 14,16
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   6Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=8242562; DOI=10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E;
RA   Wada R.K., Seeger R.C., Brodeur G.M., Einhorn P.A., Rayner S.A.,
RA   Tomayko M.M., Reynolds C.P.;
RT   "Human neuroblastoma cell lines that express N-myc without gene
RT   amplification.";
RL   Cancer 72:3346-3354(1993).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//
RX   PubMed=25884760; DOI=10.1371/journal.pcbi.1004130;
RA   Palacios-Moreno J., Foltz L., Guo A.-L., Stokes M.P., Kuehn E.D.,
RA   George L., Comb M.J., Grimes M.L.;
RT   "Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN
RT   in endosomes and lipid rafts.";
RL   PLoS Comput. Biol. 11:e1004130.1-e1004130.33(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=28636942; DOI=10.1016/j.celrep.2017.05.087;
RA   Dagg R.A., Pickett H.A., Neumann A.A., Napier C.E., Henson J.D.,
RA   Teber E.T., Arthur J.W., Reynolds C.P., Murray J., Haber M.,
RA   Sobinoff A.P., Lau L.M.S., Reddel R.R.;
RT   "Extensive proliferation of human cancer cells with ever-shorter
RT   telomeres.";
RL   Cell Rep. 19:2544-2556(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31631027; DOI=10.1016/j.ccell.2019.09.002;
RA   Qadeer Z.A., Valle-Garcia D., Hasson D., Sun Z., Cook A., Nguyen C.,
RA   Soriano A., Ma A.-Q., Griffiths L.M., Zeineldin M., Filipescu D.,
RA   Jubierre L., Chowdhury A., Deevy O., Chen X., Finkelstein D.B.,
RA   Bahrami A., Stewart E., Federico S.M., Gallego S., Dekio F., Fowkes M.,
RA   Meni D., Maris J.M., Weiss W.A., Roberts S.S., Cheung N.-K.V., Jin J.,
RA   Segura M.F., Dyer M.A., Bernstein E.;
RT   "ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition
RT   via modulation of neuronal gene signatures.";
RL   Cancer Cell 36:512-527.e9(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//